Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- ARYx to Present at the Piper Jaffray 20th Annual Healthcare Conference
Nov 25, 2008 07:02 AM
- ARYx Therapeutics Presents Clinical Data for ATI-5923 at American Heart Association Scientific Sessions 2008
Nov 14, 2008 06:46 PM
- ARYx Reports Third Quarter 2008 Financial Results
Nov 12, 2008 05:06 AM
- ARYx Therapeutics Inc. Announces $21.6 Million Private Placement -- New Funding Improves Strategic Position for Product Collaborations
Nov 12, 2008 05:02 AM
- ARYx Therapeutics Schedules Third Quarter 2008 Results and Earnings Call
Nov 05, 2008 07:09 AM
- ARYx Therapeutics Inc. Completes Enrollment in EmbraceAC Study -- Phase 2/3 Clinical Trial Comparing Anticoagulant ATI-5923 Against Warfarin
Nov 03, 2008 07:10 AM
- ARYx to Present at the Oppenheimer & Co. 19th Annual Health Care Conference
Oct 28, 2008 04:31 PM
- ARYx Therapeutics Appoints Amgen Executive to Board of Directors
Aug 29, 2008 07:01 AM
- ARYx Therapeutics, Inc. Announces Successful Results of Chronic Constipation Clinical Trial on ATI-7505
Aug 22, 2008 03:15 AM
- ARYx Reports Second Quarter 2008 Financial Results
Aug 13, 2008 03:16 AM
- Form 4/A SIMON NICHOLAS J III For: Nov 14 (10K)
Nov 25, 2008 02:22 PM
- Form 4 MPM BIOVENTURES III QP For: Nov 14 (10K)
Nov 17, 2008 07:51 PM
- Form 4 SIMON NICHOLAS J III For: Nov 14 (10K)
Nov 17, 2008 07:47 PM
- Form 4 STEINMETZ MICHAEL For: Nov 14 (10K)
Nov 17, 2008 07:44 PM
- Form 3 SANDELL SCOTT D For: Nov 14 (10K)
Nov 14, 2008 04:16 PM
- Form 4 ARYx Therapeutics, Inc. For: Oct 27 Filed by: Druzgala Pascal (10K)
Oct 28, 2008 10:21 PM
- Form 4 ARYx Therapeutics, Inc. For: Aug 28 Filed by: BEIER DAVID W (10K)
Sep 02, 2008 05:38 PM
- Form 3 ARYx Therapeutics, Inc. For: Aug 28 Filed by: BEIER DAVID W (10K)
Sep 02, 2008 05:34 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
ARYX
|
Compare to S&P
|
| YTD |
-75.48 %
|
-59.83 %
|
| 4 Weeks |
-31.90 %
|
-26.39 %
|
| 12 Weeks |
-67.80 %
|
-55.36 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 125.37 %
|
|
EPS Growth in Last Year: 102.70 %
|
|
Sales Growth in Last Quarter: 1,441.65 %
|
|
Sales Growth in Last Quarter: 1,586.92 %
|
|
|
